Related Experiment Videos

Atypical neuroleptic malignant syndrome associated with olanzapine

Roy R Reeves1, Raphael A Torres, Vincent Liberto

  • 1G.V. (Sonny) Montgomery Veterans Administration Medical Center, Jackson, Mississippi 39216, USA. roy.reeves2@med.va.gov

Pharmacotherapy
|May 16, 2002
PubMed

Insights

Neuroleptic malignant syndrome (NMS), a severe antipsychotic reaction, can occur without muscle rigidity. This case highlights atypical presentations, suggesting NMS may exist on a spectrum or differ with newer drugs.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Neuroleptic malignant syndrome (NMS) is a critical adverse drug reaction associated with antipsychotic medications.
  • Typical NMS presentation includes fever, altered mental status, muscle rigidity, and autonomic instability.
  • Antipsychotic agents are widely used for treating various psychiatric conditions.

Observation:

  • A 53-year-old male patient developed NMS while being treated with olanzapine, an atypical antipsychotic.
  • The patient presented with NMS symptoms but notably lacked muscle rigidity.
  • This atypical presentation challenges conventional diagnostic criteria for NMS.

Findings:

  • The absence of rigidity in this NMS case suggests a broader spectrum of the syndrome.
  • Atypical antipsychotics like olanzapine may induce NMS with distinct clinical features compared to conventional neuroleptics.
  • This case provides evidence supporting the theory that NMS secondary to atypical antipsychotics differs from that caused by older agents.

Implications:

  • Current diagnostic criteria for NMS, such as those in the DSM-IV, may be too restrictive.
  • More flexible diagnostic guidelines are needed to accurately identify all cases of NMS, especially those with atypical features.
  • Recognizing atypical NMS presentations is crucial for timely diagnosis and management, potentially improving patient outcomes.

Related Concept Videos